PodParley PodParley
PodParley
Charles E Geyer MD; ESMO 2025: Antibody Drug Conjugate T-DXd Brings Longer Cancer-Free Survival for Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease episode artwork

EPISODE · Mar 20, 2026 · 21 MIN

Charles E Geyer MD; ESMO 2025: Antibody Drug Conjugate T-DXd Brings Longer Cancer-Free Survival for Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease

from Audio Journal of Oncology Podcast · host Charles E Geyer MD, Breast Medical Oncologist, University of Pittsburgh Hillman Cancer Center, Pittsburgh USA, Chief Scientific Officer, NSABP Foundation

Charles E Geyer MD, at ESMO 2025, discusses DESTINY-Breast05 results, revealing trastuzumab deruxtecan (T-DXd) significantly improves disease-free survival for HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant therapy. T-DXd outperformed trastuzumab emtansin

Episode metadata supplied by the publisher feed · Published Mar 20, 2026

Embed this episode

Ready to play

Charles E Geyer MD; ESMO 2025: Antibody Drug Conjugate T-DXd Brings Longer Cancer-Free Survival for Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease

0:00 21:19

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Audio Journal of Oncology Podcast?

This episode is 21 minutes long.

When was this Audio Journal of Oncology Podcast episode published?

This episode was published on March 20, 2026.

Can I download this Audio Journal of Oncology Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!